Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

Moderna's mRNA flu vaccine showed 26.6% better efficacy than a standard flu shot in adults 50 and older during a global Phase ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

If we don’t invest in technologies like mRNA vaccines for pandemic influenza now, once a virus starts going human-to-human, ...

The latest phase 3 win is a boost for Moderna’s attempts to create a flu/COVID combination vaccine. The company withdrew a filing for FDA approval for its combo candidate last month while it waited ...

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial.   In a Phase 3 study, the ...

Moderna’s shares rallied after the biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial. In early trading, the shares were 4.3% higher at ...

The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.

Moderna's flu vaccine candidate, mRNA-1010, shows 26.6% efficacy in a Phase 3 trial for adults 50+. Read more here.

Arcturus has made progress in cost-cutting and focusing on CF and OTC deficiency. Click here to find out the factors that ...